Patents by Inventor Tobias Voigt
Tobias Voigt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11927946Abstract: In order to provide a method for predicting process deviations in an industrial-method plant, for example a painting plant, by means of which process deviations are predictable simply and reliably, it is proposed according to the invention that the method should comprise the following: automatic generation of a prediction model; prediction of process deviations during operation of the industrial-method plant, using the prediction model.Type: GrantFiled: April 29, 2020Date of Patent: March 12, 2024Assignee: Dürr Systems AGInventors: Simon Alt, Tobias Schlotterer, Martin Weickgenannt, Markus Hummel, Jens Berner, Hauke Bensch, Daniel Voigt
-
Publication number: 20230414770Abstract: The present invention relates to hydrogel prodrug compositions comprising cross-linked hyaluronic acid (HA), or a derivative or a salt thereof, wherein the cross-linker system comprises a biodegradable spacer, wherein the cross-linked HA comprises a conjugated drug-linker, and wherein the linker is capable of releasing the drug under physiological conditions. The present invention further relates to methods for preparing the hydrogel prodrug compositions. The present invention further relates to methods for treating an ocular condition using the hydrogel compositions.Type: ApplicationFiled: March 27, 2023Publication date: December 28, 2023Inventors: Sebastian STARK, Thomas KNAPPE, Harald RAU, Nicola BISEK, Burkhardt LAUFER, Samuel WEISBROD, Tobias VOIGT
-
Publication number: 20230241217Abstract: The present invention relates to a process for the irradiation of a water-insoluble conjugate comprising a polymer Z to which a plurality of moieties -L2-L1-D is covalently conjugated or of a water-insoluble complex comprising a plurality of releasably and non-covalently bound drug molecules D-H or D-OH embedded in a polymer Z?, wherein the process comprises the steps of (a) providing said conjugate or complex; and (b) exposing the conjugate or complex to ionizing radiation; wherein each -L2- is independently a chemical bond or is a spacer moiety; each -L1- is independently a linker moiety covalently and reversibly attached to -D; and each -D is independently a drug moiety.Type: ApplicationFiled: May 3, 2021Publication date: August 3, 2023Inventors: Oliver Boris STAUCH, Sebastian STARK, Tobias VOIGT, Nicola BISEK
-
Patent number: 11642415Abstract: The present invention relates to hydrogel prodrug compositions comprising cross-linked hyaluronic acid (HA), or a derivative or a salt thereof, wherein the cross-linker system comprises a biodegradable spacer, wherein the cross-linked HA comprises a conjugated drug-linker, and wherein the linker is capable of releasing the drug under physiological conditions. The present invention further relates to methods for preparing the hydrogel prodrug compositions. The present invention further relates to methods for treating an ocular condition using the hydrogel compositions.Type: GrantFiled: September 19, 2019Date of Patent: May 9, 2023Assignee: Ascendis Pharma A/SInventors: Sebastian Stark, Thomas Knappe, Harald Rau, Nicola Bisek, Burkhardt Laufer, Samuel Weisbrod, Tobias Voigt
-
Publication number: 20230123784Abstract: The present invention relates to biodegradable polyethylene glycol based water-insoluble hydrogels comprising backbone moieties which are interconnected by hydrolytically degradable bonds, the backbone moieties further comprising reactive functional groups, wherein the water-insoluble hydrogel is further characterized in that the ratio between the time period for the complete degradation of the hydrogel by hydrolysis of the degradable bonds into water-soluble degradation products comprising one or more backbone moieties and the time period for the release of the first 10 mol-% of water-soluble degradation products comprising one or more backbone moieties based on the total amount of backbone moieties in the hydrogel is greater than 1 and equal to or less than 2. The invention further relates to conjugates of such hydrogels with ligands or ligating groups, prodrugs and pharmaceutical compositions as well as their use in a medicament.Type: ApplicationFiled: December 14, 2022Publication date: April 20, 2023Applicant: Ascendis Pharma A/SInventors: Harald Rau, Ulrich Hersel, Mathias Krusch, Dirk Vetter, Tobias Voigt
-
Publication number: 20230116809Abstract: The present invention relates to pharmaceutical compositions comprising hydrogel-linked prodrug for use in the treatment, prevention and/or diagnosis a condition of the eye and ophthalmic devices comprising said pharmaceutical compositions.Type: ApplicationFiled: October 3, 2022Publication date: April 13, 2023Inventors: Thomas KNAPPE, Burkhardt Laufer, Harald Rau, Kennett Sprogøe, Tobias Voigt, Samuel Weisbrod
-
Patent number: 11559482Abstract: The present invention relates to biodegradable polyethylene glycol based water-insoluble hydrogels comprising backbone moieties which are interconnected by hydrolytically degradable bonds, the backbone moieties further comprising reactive functional groups, wherein the water-insoluble hydrogel is further characterized in that the ratio between the time period for the complete degradation of the hydrogel by hydrolysis of the degradable bonds into water-soluble degradation products comprising one or more backbone moieties and the time period for the release of the first 10 mol-% of water-soluble degradation products comprising one or more backbone moieties based on the total amount of backbone moieties in the hydrogel is greater than 1 and equal to or less than 2. The invention further relates to conjugates of such hydrogels with ligands or ligating groups, prodrugs and pharmaceutical compositions as well as their use in a medicament.Type: GrantFiled: July 30, 2010Date of Patent: January 24, 2023Assignee: Ascendis Pharma A/SInventors: Harald Rau, Ulrich Hersel, Mathias Krusch, Dirk Vetter, Tobias Voigt
-
Publication number: 20220062273Abstract: The present invention relates to a conjugate or its pharmaceutically acceptable salt, wherein said conjugate is water-in-soluble and comprises a carrier moiety Z to which one or more moieties -L2-L1-D are conjugated, wherein each -L2- is individually a chemical bond or a spacer moiety; each -L1- is individually a linker moiety to which -D is reversibly and covalently conjugated; and each -D is individually a pattern recognition receptor agonist. It further relates to pharmaceutical compositions comprising such conjugate and to their use in the treatment of cell-proliferation disorders; and to related aspects.Type: ApplicationFiled: January 3, 2020Publication date: March 3, 2022Applicant: Ascendis Pharma Oncology Division A/SInventors: Kennett SPROGØE, Yang YANG-MALTEN, Torben LESSMANN, Nicola BISEK, Samuel WEISBROD, Sebastian STARK, Tobias VOIGT
-
Publication number: 20220054478Abstract: The present invention relates to a water-insoluble controlled-release pattern recognition receptor agonist (“PRRA”) for use in the treatment of a cell-proliferation disorder, wherein the water-insoluble controlled-release PRRA is administered by intra-tissue administration, and wherein the protein levels of at least one cytokine selected from the group consisting of IL-6, CCL2 and EL-10 in plasma has a more than 10-fold lower maximum protein level within 24 hours compared to an equivalent molar dose of the corresponding free PRRA upon intra/tissue administration; and to related aspects.Type: ApplicationFiled: January 3, 2020Publication date: February 24, 2022Inventors: David B. ROSEN, Luis ZUNIGA, Juha PUNNONEN, Lars HOLTEN-ANDERSEN, Kennett SPROGØE, Yang YANG-MALTEN, Torben LESSMANN, Nicola BISEK, Samuel WEISBROD, Sebastian STARK, Tobias VOIGT
-
Publication number: 20220054477Abstract: The present invention relates to a water-insoluble controlled-release pattern recognition receptor agonist (“PRRA”) or its pharmaceutically acceptable salt or a pharmaceutical composition comprising such water-insoluble controlled-release PRRA or its pharmaceutical acceptable salt for use in the treatment of a cell-proliferation disorder, wherein the water-insoluble controlled-release PRRA, its pharmaceutically acceptable salt or the pharmaceutical composition is administered by intra-tissue administration, and wherein such intra-tissue administration results in local inflammation; and to related aspects.Type: ApplicationFiled: January 3, 2020Publication date: February 24, 2022Inventors: David B. ROSEN, Luis ZUNIGA, Juha PUNNONEN, Lars HOLTEN-ANDERSEN, Kennett SPROGØE, Yang YANG-MALTEN, Torben LESSMANN, Nicola BISEK, Samuel WEISBROD, Sebastian STARK, Tobias VOIGT
-
Publication number: 20220054476Abstract: The present invention relates to a water-insoluble controlled-release pattern recognition receptor agonist (“PRRA”) or its pharmaceutically acceptable salt or a pharmaceutical composition comprising such water-insoluble controlled-release PRRA or its pharmaceutical acceptable salt for use in the treatment of a cell-proliferation disorder, wherein the water-insoluble controlled-release PRRA, its pharmaceutically acceptable salt or the pharmaceutical composition is administered by intra-tissue administration, and wherein at least 25% of the amount of PRRA remains local in such tissue 3 days after administration; and to related aspects.Type: ApplicationFiled: January 3, 2020Publication date: February 24, 2022Inventors: David B. ROSEN, Luis ZUNIGA, Juha PUNNONEN, Lars HOLTEN-ANDERSEN, Kennett SPROGØE, Yang YANG-MALTEN, Torben LESSMANN, Nicola BISEK, Samuel WEISBROD, Sebastian STARK, Tobias VOIGT
-
Publication number: 20210338834Abstract: The present invention relates to conjugates comprising crosslinked hyaluronic acid to which a plurality of drug moieties are covalently and reversibly conjugated, wherein the hyaluronic acid exhibits a certain degree of modification and comprises degradable crosslinked moieties. It also relates to their use as medicaments and their use in the diagnosis, prevention and treatment of diseases.Type: ApplicationFiled: September 25, 2019Publication date: November 4, 2021Inventors: Sebastian STARK, Burkhardt LAUFER, Thomas KNAPPE, Tobias VOIGT, Nicola BISEK
-
Publication number: 20210330798Abstract: The present invention relates among other aspects to a conjugate or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising said conjugate or its pharmaceutically acceptable salt for use in a method of preventing or treating an infection, wherein said conjugate is water-insoluble and comprises a polymeric moiety —Z to which a plurality of moieties -L2-X0D-L1-D are covalently conjugated, wherein each -D is independently an antibiotic moiety; each -L1- is independently a linker moiety to which -D is covalently and reversibly conjugated; each —X0D— is independently absent or a linkage and each -L2- is independently either a chemical bond or a spacer moiety.Type: ApplicationFiled: September 25, 2019Publication date: October 28, 2021Inventors: Kennett SPROGØE, Sebastian STARK, Tobias VOIGT, Lars HOLTEN-ANDERSEN, Nicola BISEK
-
Publication number: 20210330807Abstract: The present invention relates to conjugates comprising backbone moieties that are crosslinked via particular crosslinker moieties to which a plurality of drug moieties are covalently and reversibly conjugated. It also relates to their use as medicaments and their use in the diagnosis, prevention and treatment of diseases.Type: ApplicationFiled: September 25, 2019Publication date: October 28, 2021Inventors: Sebastian STARK, Tobias VOIGT, Nicola BISEK
-
Publication number: 20200222547Abstract: The present invention relates to hydrogel prodrug compositions comprising cross-linked hyaluronic acid (HA), or a derivative or a salt thereof, wherein the cross-linker system comprises a biodegradable spacer, wherein the cross-linked HA comprises a conjugated drug-linker, and wherein the linker is capable of releasing the drug under physiological conditions. The present invention further relates to methods for preparing the hydrogel prodrug compositions. The present invention further relates to methods for treating an ocular condition using the hydrogel compositions.Type: ApplicationFiled: September 19, 2019Publication date: July 16, 2020Applicant: Genentech, Inc.Inventors: Sebastian STARK, Thomas KNAPPE, Harald RAU, Nicola BISEK, Burkhardt LAUFER, Samuel WEISBROD, Tobias VOIGT, Germaine FUH, Patrick KOENIG, Chingwei Vivian LEE, Daniela BUMBACA YADAV
-
Patent number: 10519226Abstract: The present invention relates to a pharmaceutical composition comprising one or more pharmaceutically acceptable excipient(s) and a VEGF neutralizing prodrug, which comprises a VEGF neutralizing biologically active moiety, for use in a method for the treatment of one or more ocular conditions.Type: GrantFiled: October 8, 2013Date of Patent: December 31, 2019Assignee: Ascendis Pharma Opthalmology Division A/SInventors: Harald Rau, Thomas Knappe, Burkhardt Laufer, Romy Reimann, Samuel Weisbrod, Kennett Sprogøe, Nicola Bisek, Sebastian Stark, Tobias Voigt
-
Patent number: 10482058Abstract: In accordance with a first aspect of the present disclosure, a biometric sensing system is provided, comprising: a sensor module configured to generate sensing data; a processing unit configured to process data received from said sensor module; wherein the sensor module and the processing unit are communicatively coupled to each other via a universal synchronous asynchronous receiver transmitter (USART) communication interface. In accordance with a second aspect of the present disclosure, a corresponding communication method is conceived. In accordance with a third aspect of the present disclosure, a corresponding computer program is provided.Type: GrantFiled: July 26, 2018Date of Patent: November 19, 2019Assignee: NXP B.V.Inventors: Thomas Suwald, Arne Burghardt, Tobias Voigt
-
Publication number: 20190262426Abstract: The present invention relates to a hydrogel-linked IL-1ra prodrug or pharmaceutically acceptable salt thereof. It further relates to a pharmaceutical composition comprising said hydrogel-linked IL-1ra prodrug, its use as medicament for the treatment of a IL-1 mediated disease, methods of application of such hydrogel-linked IL-1ra prodrugs or pharmaceutical compositions, methods of treatment, and containers comprising the hydrogel-linked IL-1ra prodrugs or pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising said hydrogel-linked IL-1ra prodrug or pharmaceutically acceptable salt thereof.Type: ApplicationFiled: January 28, 2019Publication date: August 29, 2019Applicant: Ascendis Pharma A/SInventors: Harald Rau, Joachim Zettler, Ulrich Hersel, Nora Kaluza, Mathias Krusch, Tobias Voigt
-
Publication number: 20190034378Abstract: In accordance with a first aspect of the present disclosure, a biometric sensing system is provided, comprising: a sensor module configured to generate sensing data; a processing unit configured to process data received from said sensor module; wherein the sensor module and the processing unit are communicatively coupled to each other via a universal synchronous asynchronous receiver transmitter (USART) communication interface. In accordance with a second aspect of the present disclosure, a corresponding communication method is conceived. In accordance with a third aspect of the present disclosure, a corresponding computer program is provided.Type: ApplicationFiled: July 26, 2018Publication date: January 31, 2019Inventors: Thomas Suwald, Arne Burghardt, Tobias Voigt
-
Patent number: 10093011Abstract: Disclosed is an oscillatingly driven machine tool including a tool spindle that is mounted pivotably about its longitudinal axis, further including a drive motor that is coupled to a hydraulic generator for generating an oscillating fluid flow which drives a hydraulic motor being configured as a rotor blade motor. The rotor blade motor drives the tool spindle in such a way that the tool spindle rotates oscillatingly about its longitudinal axis. The rotor blade motor includes symmetrically arranged rotor blades that are disposed at regular angular distances with respect to each other.Type: GrantFiled: May 12, 2016Date of Patent: October 9, 2018Assignee: C. & E. Fein GmbHInventors: Steffen Noack, Tobias Voigt